The need for an HIV vaccine continues to be a global health urgency.
- Today millions of people are living longer, healthier lives, thanks to the dramatic increase in availability of life-saving HIV care, treatment globally. However, the rate of new HIV infections remains flat, and AIDS still kills 1 million people each year. Even a partially effective vaccine will save lives [7, 8].
- About half of all people living with HIV are currently receiving life-saving antiretroviral (ARV) treatment. This is a tremendous success story. But it also means that treatment and prevention tools are not getting to half of all people living with HIV. As more people become infected with HIV, the cost of providing lifelong ARV treatment will continue to grow. This is particularly burdensome for developing countries already adversely affected by the epidemic. And many people with HIV don’t even know they’re infected. 
- Increasingly, people are becoming resistant to the most common ARVs. In some regions, these resistant strains are becoming alarmingly frequent, raising the concern that increasing numbers of HIV-infected individuals will not respond to treatment with the most common and affordable ARVs. More and better tools, including a vaccine, are needed to curb the epidemic [9, 10].
- The world’s largest-ever generation of young people is aging towards adolescence and young adulthood. Experts warn that an increase in new HIV infections is inevitable unless rates of viral suppression are sharply increased and rates of HIV transmission are substantially lowered. [11,12].
Spread the word
It's an exciting time in #HIV vaccines! The new generation of vaccines being tested this year will help scientists home in on the best approaches to #EndAIDS4Good. #VaccinesWork #HVAD2018 bit.ly/iavihvad2018
On #HVAD2018 we’re at a turning point in the search for an #HIV vaccine. Keeping the momentum is critical if we want to #EndAIDS4Good! bit.ly/iavihvad2018
The search for an HIV vaccine is transforming the way scientists think about treatment, prevention, and cure – and not just for #HIV. #VaccinesWork #EndAIDS4Good #HVAD2018 bit.ly/iavihvad2018
To truly #EndAIDS4Good we need all of the tools at hand, and more. We need a vaccine. #VaccinesWork #HVAD2018 bit.ly/iavihvad2018
Even a partially effective #HIV vaccine would save millions of lives when combined with the currently available and emerging approaches for prevention #VaccinesWork #EndAIDS4Good #HVAD2018 bit.ly/iavihvad2018
Sample Facebook & LinkedIn Posts
It’s an exciting time in HIV vaccine science! This year marks first time that HIV vaccine candidates that were rationally designed to induce antibodies against the virus will ever be tested in humans. bit.ly/iavihvad2018
May 18 is HIV Vaccine Awareness Day. Did you know that no infectious disease in history has ever ended without a vaccine? Vaccines work. That’s why we need one for AIDS. bit.ly/iavihvad2018
An HIV vaccine remains an urgent global health need in 2018. With two large HIV vaccine trials ongoing in sub-Saharan Africa and two more soon to start, the world is at a turning point. Let’s keep up the momentum! bit.ly/iavihvad2018
1. HVTN studies. https://www.hvtn.org/en/science/HVTN-studies.html.
2. Walker, L.M., et al., Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009. 326(5950): p. 285-9.
3. Rappuoli, R., et al., Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. The Journal of Experimental Medicine, 2016. 213(4): p. 469-481.
4. Gray, E.S., et al., The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol, 2011. 85(10): p. 4828-40.
5. Harmon, T.M., et al., Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries. PLoS One, 2016. 11(1): p. e0146387.
6. Medlock, J., et al., Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proc Natl Acad Sci U S A, 2017. 114(15): p. 4017-4022.
7. UNAIDS, Prevention Gap Report. 2016. http://www.unaids.org/en/resources/documents/2016/prevention-gap
8. Abdool Karim, Q., C. Baxter, and D. Birx, Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2017. 75: p. S17-S26.
9. Gupta, R.K., et al., HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis, 2018. 18(3): p. 346-355.
10. Gupta, R.K., et al., Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet, 2012. 380(9849): p. 1250-8.
11. Slogrove, A.L., et al., Living and dying to be counted: What we know about the epidemiology of the global adolescent HIV epidemic. Journal of the International AIDS Society, 2017. 20(Suppl 3): p. 21520.
12. Granich, R., et al., 90-90-90 and ending AIDS: necessary and feasible. Lancet, 2017. 390(10092): p. 341-343.